Retinitis Pigmentosa 2 (RP2) Cell Models for Research

Retinitis Pigmentosa 2 (RP2) is a rare inherited retinal dystrophy caused by mutations in the RP2 gene. The global prevalence of retinitis pigmentosa (RP) is approximately 1 in 4,000, affecting over 1.5 million people worldwide (WHO). RP2 accounts for about 10-15% of X-linked RP cases, with an estimated prevalence of 1 in 100,000. The disease typically presents in early adulthood with night blindness and progressive loss of peripheral vision, leading to legal blindness by mid-adulthood. There is no cure, and current treatments are limited to supportive care and gene therapy clinical trials. The clinical impact is significant, as patients experience progressive vision loss, impacting quality of life and independence.

RP2 is an ideal model for studying photoreceptor biology and retinal degeneration mechanisms. The RP2 gene encodes a protein involved in ciliary trafficking and lipid modification, and its dysfunction leads to photoreceptor cell death. Research focuses on understanding the molecular pathways underlying RP2-associated degeneration, developing gene therapies, and identifying potential drug targets. Public datasets, such as those from the NCBI Gene and ClinVar, provide valuable information on RP2 mutations and expression patterns. Open questions include the precise role of RP2 in ciliary function and the development of effective therapeutic strategies.

RP2 protein is involved in several key pathways:

• • Ciliary trafficking: RP2 localizes to the basal body of photoreceptor cilia and is involved in the transport of proteins along the cilium. Mutations disrupt this process, leading to defective photoreceptor function.
• • Lipid modification: RP2 acts as a GTPase-activating protein (GAP) for ARL3, regulating the release of lipid-modified proteins from the Golgi. Defects in this pathway impair protein trafficking.
• • Photoreceptor survival: Disruption of these pathways triggers apoptosis in photoreceptor cells, leading to retinal degeneration.

Data from ClinVar and NCBI Gene.

RP2 dysfunction affects multiple signaling networks:

• • ARL3-GTPase pathway: RP2 acts as a GAP for ARL3, regulating the release of lipidated proteins. Mutations lead to mislocalization of these proteins.
• • Ciliary signaling: Defects in ciliary trafficking impair signaling pathways such as Hedgehog and Wnt, which are critical for photoreceptor function.
• • Apoptotic pathways: Loss of RP2 function triggers endoplasmic reticulum stress and activation of caspases, leading to photoreceptor cell death.

Organoids derived from patient iPSCs are also used to model RP2, providing a more physiologically relevant 3D environment.

• • RP2 knockout mouse: Developed by targeted disruption of the RP2 gene, recapitulating retinal degeneration.
• • RP2 mutant zebrafish: Used to study ciliary defects.
• • Induced models: Pharmacological induction of retinal degeneration in rodents.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise RP2 mutations. For example:

• • RP2 knockout cell lines: Generated by introducing frameshift mutations in the RP2 gene, resulting in loss of function.
• • RP2 knock-in cell lines: Introduction of specific point mutations (e.g., p.R118H) to model patient-specific variants.

These gene-edited models are commercially available from various sources, providing sequence-verified and quality-controlled tools for research. They are essential for studying the molecular consequences of RP2 mutations and for drug screening.

RP2 knockout and knock-in cell lines are used to validate the functional impact of RP2 mutations. For example, studies have shown that RP2 knockout leads to mislocalization of ARL3 and impaired ciliary trafficking. These models allow researchers to investigate the role of RP2 in photoreceptor biology and identify downstream effectors.

Isogenic pairs (wild-type vs. RP2 knockout) are used in high-throughput screens to identify compounds that rescue the phenotype. For instance, small molecules that promote ciliary trafficking or inhibit apoptosis could be potential therapeutic leads. Additionally, these models can be used to study resistance mechanisms to existing therapies.

CRISPR-based synthetic lethality screens using RP2 knockout cells can identify genes that are essential for cell survival in the absence of RP2. These genes may serve as novel drug targets or biomarkers for disease progression.